Sector News

After denials, Bayer eyeing consumer brand and animal health selloffs: report

November 28, 2018
Life sciences

It was only two weeks ago that Bayer CEO Werner Baumann told reporters that the company wasn’t discussing “any strategic considerations” for its troubled animal health and consumer units. But behind the scenes, Bayer’s executives may be plotting big changes for those businesses, according to a new report.

Bayer is planning a board meeting this week, during which it will consider options for consumer and animal health, according to Reuters, which quoted anonymous sources. The discussion will include a proposal to cast off some of its consumer brands, the news service reported.

A spokesperson for Bayer declined to comment, saying in an email to FiercePharma that the company does not comment on market rumors.

The animal health revelation isn’t entirely surprising, seeing as Wall Street analysts have been predicting Bayer would make that move for several months now. But the possibility that Bayer might retreat from consumer health, where it has long maintained storied brand names, shows just how heavily its $63 billion Monsanto buy is weighing on the company.

Bayer’s in-house dealmakers are considering selling off consumer brands in countries where Bayer “deems its business to be too small to thrive in the long term,” according to one of the sources Reuters quoted.

Fact is, Bayer’s consumer health portfolio seems to be suffering all around. The unit’s top seller, allergy treatment Claritin, fell nearly 4% on a currency-adjusted basis in the first nine months of the year. The Coppertone sunscreen line was down 6%. Those are both products Bayer picked up in its $14 billion acquisition of Merck’s consumer health portfolio in 2014.

Even Bayer aspirin is suffering. Sales of that product dropped nearly 12% year-over-year in the third quarter to €98 million. Earlier this year, Baumann admitted Bayer is struggling to keep up with changing consumer-buying behaviors, including a massive shift to online ordering.

Bayer did beat overall estimates in the quarter, and Baumann reaffirmed the company’s full-year outlook, but some analysts pointed out that the company is facing other challenges that will be hard to overcome. Bayer’s animal health business—the world’s fifth-largest—saw its revenues fall a surprising 15% year over year to €304 million during the most recent quarter, for example. That’s one of the reasons Bernstein analysts declared “the beat is low quality” in a note to investors.

In October, Bernstein analyst Wimal Kapadia argued that Bayer should consider a split-up, figuring it would be the only way for the company to grow while it’s burdened with debt from the Monsanto buy. If crop science, animal health and consumer were separated from the pharma division, all of the units would have a chance to regain fair valuations, and Bayer could earn cash to pour into its drug pipeline, the analyst suggested.

Kapadia estimates Bayer’s animal health unit could bring in at least €6 billion ($6.9 billion). If it divests the unit, it will join a long line of pharma companies that have separated themselves from animal health. Most recently, Eli Lilly filed for an initial public offering of its animal health business, Elanco, which is expected to be completed by the end of this year. Pfizer spun off Zoetis in 2013, and in 2016 Sanofi handed its animal health business to Boehringer Ingelheim in return for BI’s consumer unit.

The potential value of a Bayer consumer castoff will depend, of course, on the specifics of the plan. Investors will be expecting to hear more on from Baumann on Dec. 5 at a meeting in London, where the company will provide an update on its strategy post-Monsanto takeover.

By Arlene Weintraub

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach